Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study to demonstrate remyelination (the formation of new myelin on axons) following an inflammatory injury in humans. These data will be presented at the 67th Annual Meeting of the […]

Read More »

Divorce tied to increased heart attack risk

  (Reuters Health) – Women who have been divorced once, or men who have been divorced at least twice, are more likely to have a heart attack than people who get and stay married, according to a new study. “The negative health consequences of divorce have been known for some time,” said lead author Matthew […]

Read More »

Celprogen Introduces a Novel Pharmacological Inhibitor CEP1430 for Human Pancreatic Cancer Patients

TORRANCE, Calif.–(BUSINESS WIRE)–Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed a novel pharmacological Inhibitor CEP1430 synthetic molecule that is capable of inhibiting the growth and proliferation of the human pancreatic cancer tumor. This molecule can […]

Read More »

FDA Advisory Committee Reviews Takeda’s Alogliptin EXAMINE Cardiovascular Safety Outcomes Trial

DEERFIELD, Ill. and OSAKA, Japan, April 14, 2015 /PRNewswire/ — Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that members of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States (U.S.) Food and Drug Administration (FDA) convened to review one of the first cardiovascular (CV) outcomes trials (CVOT) […]

Read More »

GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine

Strategy Intended to Accelerate Development of an HIV Vaccine for the Americas and Western Europe ATLANTA, GA–(Marketwired – Apr 14, 2015) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced its intention to pursue a dual pathway for advancing its […]

Read More »

NorthShore University HealthSystem Launches Comprehensive Center for Personalized Medicine, Ushering in New Era in Medical Care

Trailblazing Initiative to Treat and Prevent Illness Based on Patient’s Genetic, Biologic Makeup EVANSTON, IL–(Marketwired – April 14, 2015) – NorthShore University HealthSystem (NorthShore) today launched one of the most comprehensive personalized medicine programs in the country that utilizes an individual’s health history and DNA to better predict, prevent and diagnose certain diseases, and develop […]

Read More »

Lilly Study: Livalo Helps HIV Patients

New Data Showed Livalo (Pitavastatin) 4 Mg Had Neutral Effects on Fasting Serum Glucose and Hba1c Levels in HIV-Infected Adults With Dyslipidemia Study results presented at ENDO 2013 Annual Meeting SAN FRANCISCO, June 17, 2013 /PRNewswire/ — Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) announced results of a pre-specified safety analysis […]

Read More »

GlaxoSmithKline: Offsetting Results

GlaxoSmithKline is succeeding with newly launched products and strong R&D flow while struggling with U.S. pricing and competitive pressures.

Read More »

22nd Annual Report 2013

Top 100 Biotechnology Companies

Biotech industry growth is bolstered by increased R&D spending, an upswing of approved first-in-class medicines, elevated Wall Street valuations, and continued forging of pipeline alliances with Big Pharma.

Read More »

Future blockbusters 2013

Click to download the PDF to view the full issue An upswing in NME approvals is an encouraging sign for an industry trying to overcome mega-brand patent expirations and a lag in research and development productivity. R&D expenditure growth for the industry as a whole has reached a stagnant state, though many companies remain dedicated […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom